-
Sector Analysis
Fabry Disease - Opportunity Assessment and Forecast
Fabry Disease, or FD for short, refers to a rare, inherited X-linked lysosomal storage disease (LSD) whereby mutations in the galactosidase-α (GLA) gene encoding the lysosomal enzyme α-GAL A. Due to a deficiency or absence of GLA, an enzyme substrate, primarily globotriaosylceramide (Gb3) accumulates throughout the blood vessels, other tissues, and organ. Clinical manifestations include, but are not limited to, renal, cardiac and cerebrovascular complications, as well as pain, angiokeratoma, gastrointestinal disturbance, an overall reduce quality of life and early...
-
Sector Analysis
Pompe Disease - Opportunity Assessment and Forecast to 2030
This report covers 3MM (US, Germany and Japan) and provides an Excel-based forecast model for the Pompe Disease market through 2030.
-
Sector Analysis
Diabetic Retinopathy - Global Drug Forecast and Market Analysis to 2029
Diabetic retinopathy (DR) is a sight-threatening, prevalent complication of type 1 and 2 diabetes which is characterized by damage to the small blood vessels in the retina. As the most common microvascular complication of diabetes, more than 60% of patients will experience DR within 20 years of developing diabetes. DR the principal cause of preventable vision loss in working-age adults around the world. There are two major clinical stages of diabetic retinopathy: a less severe subtype known as non-proliferative diabetic...
-
Sector Analysis
Transthyretin Amyloidosis - Global Drug Forecast and Market Analysis to 2029
Amyloidosis is a protein confirmation disorder that results in the build-up of insoluble amyloid proteins in tissues. This build-up can be fatal as it leads to disruption of organ systems and causes oxidative stress within the body. There are various forms of amyloidosis, each associated with the protein involved and the underlying cause of protein mis-folding. Amyloid aggregates affect different organs, most commonly the heart, kidney and liver whilst also affecting the peripheral, autonomic and gastro-intestinal (GI) systems. Most amyloidosis...
-
Sector Analysis
PharmaPoint: Dyslipidemia – Global Drug Forecast and Market Analysis to 2025
GlobalData estimates sales of dyslipidemia therapeutics to be approximately $11.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The dyslipidemia market will grow at a strong CAGR of 10.1% over the forecast period, reaching sales of $29.2B by 2025. The US is the largest market for dyslipidemia therapies, contributing approximately 61.5% of total sales in the base year. GlobalData expects uptake of the revolutionary class of PCSK9 targeting biologics to be the strongest driver of growth in...
-
Sector Analysis
PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2026
While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, GlobalData expects this market to undergo substantial growth between 2016 and 2026, doubling over the forecast period. The main driver of this enormous expansion will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle. The second largest driver will be physicians’ efforts to delay disease progression and reduce the...
-
Sector Analysis
OpportunityAnalyzer: Growth Hormone Deficiency – Opportunity Analysis and Forecasts to 2026
Growth hormone deficiency (GHD) is a rare endocrine disorder characterized by inadequate secretion of growth hormone (GH) from the anterior pituitary gland. It is a heterogeneous disorder that may present in childhood (pediatric GHD) or later in adult life (adult GHD). Reduced GH secretion predominantly results in stunted linear growth in children; therefore, the standard-of-care GH replacement therapy serves to normalize height in children. Adults with GHD generally demonstrate biochemical abnormalities, which can also be successfully treated with recombinant GH....
-
Sector Analysis
OpportunityAnalyzer: Hyperparathyroidism – Opportunity Analysis and Forecasts to 2025
Hyperparathyroidism (HPT) is a common endocrinal disorder characterised by excessive plasma levels of parathyroid hormone (PTH) stemming from overactivity of the parathyroid glands. The parathyroid glands, of which there are four, regulate physiological calcium homeostasis through a negative feedback mechanism involving PTH secretion. HPT is classified into either primary, secondary, or tertiary, and it is important to differentiate between the three as their underlying aetiology, pathology, and treatment differ. Primary HPT (PHPT), which is characterised by hypercalcemia, results from the...
-
Sector Analysis
Opportunity Analyzer: Diabetic Foot Ulcers – Opportunity Analysis and Forecast to 2025
GlobalData estimates sales of diabetic foot ulcer (DFU) and diabetic foot infection (DFI) drugs to be approximately $292.1M across the 7MM in 2015, encompassing the US, 5EU, and Japan. DFU sales alone accounting for $118.7M across the 7MM. The DFU, DFI market will grow at a CAGR of 11.6% over the forecast period, reaching sales of $873.4M by 2025. The US is the largest market for DFU, DFI therapies, contributing approximately 62% of total sales in the base year. GlobalData...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.